TIDMMDC
RNS Number : 8010U
Mediclinic International plc
31 July 2020
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", or the "Company", or the "Group")
31 July 2020
Replacement: The following announcement replaces the
announcement released on 17 June 2020 at 3.30pm (UK) under RNS
number 2768Q. The amount settled per share and the cash settlements
(including dividend equivalents) have been amended. The corrected
announcement is set out below and all other details remain
unchanged.
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This notification sets out details of the vesting and settlement
of awards granted to the executive directors on 15 June 2018 in
respect of the deferred element of the Company's 2017 short-term
incentive ("STI"). These awards, denominated in shares, vested on
15 June 2020 and will be settled in cash on 26 June 2020 based on
the middle-market quotation of a share on 15 June 2020, being
GBP2.68 per share. The amount settled included the value of
dividends attributable to the vested shares during the period
between the date of grant and the date of vesting, being a total of
15.8 pence per share.
The table below sets out the number of shares vested for the
directors who were granted awards under the STI on 15 June 2018
together with the corresponding cash settlement.
Name Number of shares Cash settlement
vested (including
dividend
equivalents)
Petrus Jurgens 27 236 GBP77,350
Myburgh(1)
----------------- ----------------
Daniël 45 811 GBP130,103
Petrus Meintjes(2)
----------------- ----------------
Notes:
(1) As Group Chief Financial Officer, Mr Myburgh is required to
build and maintain a minimum holding of shares equivalent to a
value of 200% of his annual base compensation. As that threshold
had not been met under the Company's Remuneration Policy, Mr
Myburgh was required to apply 50% of the net of tax value of the
vested shares to the purchase of ordinary shares in Mediclinic. As
announced on 10 June 2020, Mr Myburgh purchased 7 500 shares on 8
June 2020 to fulfil this obligation.
(2) Mr Meintjes was an executive director of the Company at the
time the award was granted and is now a non-executive director.
The notifications below are made in accordance with Articles
19.1 and 19.3 of the Market Abuse Regulation.
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Petrus Jurgens Myburgh
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Group Chief Financial Officer of the Company
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Vesting and cash settlement of award over
transaction ordinary shares in Mediclinic International
plc granted in 2018 under the Company's
short-term incentive scheme
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 27 236
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
27 236
GBPnil
----------------------- ---------------------------------------------
e) Date of the 15 June 2020
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Daniël Petrus Meintjes
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Non-executive director of the Company
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Vesting and cash settlement of award over
transaction ordinary shares in Mediclinic International
plc granted in 2018 under the Company's
short-term incentive scheme
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 45 811
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
45 811
GBPnil
----------------------- ---------------------------------------------
e) Date of the 15 June 2020
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
About Mediclinic International plc
Mediclinic is a diversified international private healthcare
services group, established in South Africa in 1983, with divisions
in Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for
all their healthcare needs.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the continuum of care in such a
way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical
practitioners, funders and regulators of healthcare in each of its
markets.
At 1 July 2020, Mediclinic comprised 76 hospitals, eight
sub-acute and specialised hospitals, 15 day case clinics and 18
outpatient clinics. Hirslanden operated 17 hospitals and three day
case clinics in Switzerland with more than 1 800 inpatient beds;
Mediclinic Southern Africa operations included 52 hospitals (three
of which in Namibia), eight sub-acute and specialised hospitals and
10 day case clinics (four of which operated by Intercare) across
South Africa, and more than 8 700 inpatient beds; and Mediclinic
Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the
UAE.
The Company's primary listing is on the London Stock Exchange
("LSE") in the UK, with secondary listings on the JSE Ltd in South
Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the UK and listed
on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Kerry Higgins
+44 (0) 20 7954 9583
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address : 6(th) Floor, 65 Gresham Street, London,
EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker : Morgan Stanley & Co International plc and
UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of
FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHWPUAAMUPUGGG
(END) Dow Jones Newswires
July 31, 2020 10:00 ET (14:00 GMT)
Grafico Azioni Mediclinic (LSE:MDC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Mediclinic (LSE:MDC)
Storico
Da Apr 2023 a Apr 2024
